

## DAFTAR PUSTAKA

1. Rapuano CJ, Stout JT MC. Glaucoma. In: Tanna AP, Boland MV, Giaconi JA et al, editor. American Academy Of Ophthalmology. San Francisco: AAO; 2021. p. 3–111.
2. Artini, W. & Dame. Glaucoma Caused Blindness with Its Characteristic in Cipto Mangunkusumo Hospital. Jakarta: Jurnal Oftalmologi Indonesia. 2011; 7(5): Halaman 189-193
3. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–93.
4. Thanm et al. Prevalence of Open Angle Glaucoma Among adult in the United State. Arch Ophthalmol. 2011. 129(9). pp1224
5. Wilson M, Kosoko O, Cowan CL. Progression of visual field loss in untreated glaucoma patient and suspect in St. Lucia, West India. American Journal Ophthalmology. 2002. 134(3) : 399-405
6. Benjamin MD, Crawley LPahlitzch, et al. Glaucoma : The Retina and Beyond. Acta neuro-Ophthalmology. 2016(132) : 807-826.
7. Kemenkes RI. Pusat Data dan Informasi Kementrian Kesehatan RI. 2019.
8. Soto I, Howell GR. The complex role of neuroinflammation in glaucoma. Cold Spring Harb Perspect Med. 2014;4(8):14.
9. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83:1–26.
10. Beykin G, Goldberg JL. Molecular Biomarkers for Glaucoma. Curr Ophthalmol Rep. 2019;7(3):171–6.
11. Pinazo-Duran MD, Shoaie-Nia K, Zanon-Moreno V, Sanz-Gonzalez SM, del Castillo JB, Garcia-Medina JJ. Strategies to Reduce Oxidative Stress in Glaucoma Patients. Curr Neuropharmacol. 2017;16(7):903–18.

12. Stoskuvienė A. Evaluation of Glaucomatous Structural Change. Biophysical Properties in Glaucoma. Springer. Switzerland. 2019: pp 80-86.
13. Benjamin MD, Crawley LPahlitzsch, et al. Glaucoma : The Retina and Beyond. *Acta neuro-Ophthalmology*. 2016(132) : 807-826.
14. James E Morgan. Retinal ganglion Cell degeneration in glaucoma : an opportunity missed. A review. *Clinical and experimental ophthalmology*. 2012;40:364-368
15. Amit Meshi, Dafna Goldenberg, Sharon Armarnik, Ori Segal, Noa Geffen. Systematic review of macular ganglion cell complex analysis using spectral domain optical coherence tomography for glaucoma assessment. *World J Ophthalmol* 2015 May 12; 5(2): 86-98
16. Elmore Susan. Apoptosis: A Review Of Programmed Cell Death. In: National Institute of Health. Volume 35. Number 4. NIH Public Access Laboratory of Experimental Pathology; North California, USA: 2007. Pp 495-516.
17. Grieb P. Neuroprotective Properties Of Citicoline: Facts, Doubts And Unresolved Issues. Current Opinion. In: Citicoline for Neuroprotection. CNS Drugs. Department of Experimental Pharmacology, Mossakowski. Medical Research Centre, Polish Academy of Sciences. Adis; Poland: 2014. pp 185-193.
18. Saver JL. Citicoline: Update On A Promising And Widely Available Agent For Neuroprotection And Neurorepair. Treatment Update. In: Reviews In Neurological Disease. Volume 5. Number 4. UCLA Stroke Center and Department of Neurology. MedReviews; Los Angeles: 2008. pp 167-177.
19. Garcia E et al. Programmed Cell Death of Retinal Ganglion Cell During Experimental Glaucoma. *Elvisier Science*. 1995. pp 33-44
20. Navarro et al. Retinal Ganglion Cell Death after Different Transient Periods of Pressure- induced ischemia and survival interval. *Invest Ophthalmol*. 1996
21. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and Recovery. In: Recent Data at the Bench On Citicoline. The Unidad De Investigacion Neurovascular.

- Departamento De Farmacologia, Facultad De Medicina. American Heart Association Inc; Spain: 2011. pp 33-35
22. Parisi V, Oddone F, Ziccardi L, Roberti G, Coppola G, Manni G. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Review Article. In: Current Neuropharmacology. Volume 15. Italian Ministry of Health and Fondazione Roma. Bentham Science Publishers; Italy: 2017. pp 1-14
  23. Sihota R, Angmo D, Ramaswamy D dkk Simplifying Target Intraocular Pressure for Different Stages of Primary Open Angle Glaucoma and Primary Angle Closure Glaucoma. Indian Journal of Ophthalmology.2018(66). Pp.495-505
  24. Parisi V.Electrophysiological Assesment of Glaucomatous Visual Disfunction During Treatment with Citicolin.Ophthalmologica.2005.pp.91-102
  25. Giraldi JP et al.Therapeutic Value of Citicoline in the Treatment of Glaucoma.International Ophthalmology.1989.13.pp109-112
  26. Redjak R et al. Oral citicoline Treatment Improve Visual Pathway Function in Glaucoma Med Sci Monit.2003.9(3).p124-128
  27. Parisi V et al. Evidence of the neuroprotective Role of Citicolin in Glaucoma Patient in Progress in Brain research.Chapter 37.Vol 73.2008.pp541-554
  28. Oshitari, T.; Fujimoto, N.; Adachi-Usami, E. Citicoline has a pro-TECTIVE effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport, 2002, 13(16), 2109-2111
  29. Matteuci et al. Neuroprotective effects of Citicoline in Vitro Model of RetinalNeurodegeneration.InternationalJournalMolecularScience.2014.15(4).pp 6286-6297
  30. Francesco O. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. Pharmaceutical 14-281 .2021
  31. Hondrizal.Pengaruh lama pemberian citicolin dalam memepbaiki RNFL dan lapang pandang pada POAG.Bagian Ilmu Kesehatan Mata .Uneversitas Andalas.2011

32. Steven J et al. Primary Open-Angle Glaucoma Preferred Practice Pattern American academy of ophthalmology Preferred Practice Pattern Panel. 2019-2020
33. Schuster Ak et al. The Diagnosis and Treatment of Glaucoma. *Dtsch Arztebl Int.* 2020;117(13).pp.225-234
34. Kansky JJ. Glaucoma: Open-Angle Glaucoma. *Clinical Ophthalmology: A systemic Approach.* Philadelphia: Elsevier, 9th ed. 2020:246-51
35. Maiciulaitiene R, Januleviciene I. Correlation Between Structure and Function in Glaucomatous Damage. *Biophysical Properties in Glaucoma.* Switzerland: Springer, 2019: pp 145-9.
36. Morgan J. Pathogenesis of Glaucomatous Optic Neuropathy. In *Glaucoma Medical Diagnosis & Therapy.* Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG. Elsevier; 2009:pp.45-53
37. Levin LA. Chapter 19 Glaucoma. In: *Duane's Ophthalmology.* Tasman W, Jaeger EA. Philadelphia: Lippincott William & Wilkins; 2007:1341-45
38. Cantor LB, Rapuano CR, Colin AM. Glaucomatous optic neuropathy. In: *Basic and clinical science course section 10. American Academy of Ophthalmology.* San Fransisco. 2019-2020: 3-16
39. Tanna AP, Boland MV, Giaconi JA, Krishnan C, Lin SC, Medeiros F, et al. Clinical Evaluation and Imaging of the Posterior Segment: Optic Nerve, Retinal Nerve Fiber Layer, and Macula in Glaucoma, In: *Basic and clinical science course section 10. American Academy of Ophthalmology.* San Fransisco. 2020-2021:59
40. Nakla M, Caprioli j, Morgan JA. Glaucomatous Optic Neuropathy. In: *Glaucoma Science and Practice;* Thieme; New York; 2003. p 94-102.
41. Mills P, Budenz DL, Lee PP dkk. Categorize The Stage of Glaucoma From Prediagnosis to End staging Disease. In *Am J Ophthalmol.* 2006(141).pp 24-30
42. Weinreb Nh. Anatomy, physiology, and Pathophysiology. In *Handbook of Glaucoma.* Taylor and Francis e Library. 2003.p.11-17

43. Luo X et al. Ocular Blood Flow Autoregulation Mechanism and Methods. *J Ophthalmol*.2015;1-21
44. Sihota R, Angmo D, Ramaswamy D dkk Simplifying Target Intraocular Pressure for Different Stages of Primary Open Angle Glaucoma and Primary Angle Closure Glaucoma. *Indian Journal of Ophthalmology*.2018(66). Pp.495-505
45. Susanna R, Vessani Roberto M. Staging Glaucoma Patient: Why and How?. *The Open Ophthalmology Journal*.2009(3): 59-64
46. Agarwal A, Kumar DA. History, Principles, and Instrumentation of Optical Coherence Tomography in: *Essential of OCT in Ocular Disease*. New York: Thieme Medical Publisher; 2016: 2-8
47. Cantor LB et al. The eye. In *Basic and Clinical science course section 2*. America Academy of Ophthalmology. San Fransisco.2021. p3-16
48. Stamper RL, Lieberman MF, Drake MV. *Diagnosis and Therapy of the glaucoma*. Mosby:Elsevier,2009:153-60
49. Sinai MJ. *Direct Ganglion Cell Assesment with the RTVue:The ganglion cell Complex analysis*.2015.
50. Kauffman P. *Retina Section*. In: *Adler's Physilogy of The Eye*. Retina. Mosby,2002.pp.371-380
51. James EM. *Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review*. *Clinical and Experimental Ophthalmology* 2012; 40: 364–368
52. Esporcatte BL, Kara-José AC, Melo LA, Pinto LM, Tavares IM. *The Estimates of Retinal Ganglion Cell Counts Performed Better than Isolated Structure and Functional Tests for Glaucoma Diagnosis*. *Hindawi<sup>[1]</sup>Journal of Ophthalmology<sup>[1]</sup>*. Brazil. 2017:1-6
53. Mwanza J-C, Durbin M, Budenz D, Girkin C, Leung C, Liebmann J, et al. *Profile and Predictors of Normal Ganglion Cell–Inner Plexiform Layer*

Thickness mMeasured With Frequency Domain Optical Coherence Tomography. *Investig Ophthalmol Vis Sci.*2011.52(11) : 7872-9

54. James EM. Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review. *Clinical and Experimental Ophthalmology* 2012; 40: 364–368
55. Grieb P. Neuroprotective Properties Of Citicoline: Facts, Doubts And Unresolved Issues. Current Opinion. In: *Citicoline for Neuroprotection*. CNS Drugs. Department of Experimental Pharmacology, Mossakowski. Medical Research Centre, Polish Academy of Sciences. Adis; Poland: 2014. pp 185-193.
56. Saver JL. Citicoline: Update On A Promising And Widely Available Agent For Neuroprotection And Neurorepair. Treatment Update. In: *Reviews In Neurological Disease*. Volume 5. Number 4. UCLA Stroke Center and Department of Neurology. MedReviews; Los Angeles: 2008. pp 167-177.
57. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and Recovery. In: *Recent Data at the Bench On Citicoline*. The Unidad De Investigacion Neurovascular. Departamento De Farmacologia, Facultad De Medicina. American Heart Association Inc; Spain: 2011. pp 33-35.
58. Miller Neil R. Optic Nerve Protection, Regeneration, and Repair in The 21st Century: LVIII Edward Jackson Memorial Lecture. *Neuro- Ophthalmology Unit*. In: *American Journal of Ophthalmology*. The Wilmer Eye Institute. Elsevier; Maryland: 2001. pp 811-817
59. Shaffie N, Shabana ME. Role of Citicoline as a Protective Agent on Toluene-induced Toxicity in Rats. Original Article. In: *Journal of The Arab Society for Medical Research*. Number 14. Cairo, Egypt. 2019. pp 14-24.
60. Zubair M, Ahmad I, Rahman MH, Akhtar KM. Ethambutol induced Histological Changes in Optic Nerve of Rabbit. In: *Original Article.A.P.M.C* Volume 4. Number 2. 2010. pp 122 - 127.
61. Ross MH, Pawlina W. *Histology a Text and Atlas (sixth edition)* Philadelphia : Wolters Kluwer Lippincot Williams and Wilkins.2011

- 62.. Tian, K., Shibata-Germanos, S., Pahlitzsch, M. & Cordeiro, M. F. Current perspective of neuroprotection and glaucoma. *Clin. Ophthalmol.* 9, 2109–2118 (2015).
63. Carl Zeiss Meditec I. Cirrus HD-OCT : How to read the Cirrus reports [Internet]. Review Literature And Arts Of The Americas. California: Carl Zeiss Meditec; 20ade11. p. 1–13.
64. Jaffe JG, Caprioli J. Optical Coherence Tomography to detect and manage retinal disease and glaucoma. In *OCT for Retina and Glaucoma, USA:Elsevier Mosby,2006:1533-551*
65. Yolanda S, Primitasari Y, Sari DR. Characteristics of Primary Open Angle Glaucoma Patients in Dr. Soetomo General Hospital Surabaya. *Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga.* 2021; 12(01): 7-9
66. Salsabila AI, Gandasubrata AP, Rifada M. Clinical Characteristics and Managements of Primary Open-Angle Glaucoma Patients at National Eye Center, Cicendo Eye Hospital, Bandung, Indonesia. *J Med Health.* 2023: 5(01): 43-55.
67. Geede SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Glaucoma preferred practice pattern: development process and participants. *American Academy of Ophtalmology.* 2020: 72-152.
68. Patil J, Chaudari S. Determination of Glaucoma Grade with Cup to Disc Ratio. *Acta Scientific Ophthalmology* 4.3. 2021: 44-53.
69. Mahabadi N, Foris LA, Tripathy K. Open Angle Glaucoma. In: *StatPearls.* Treasure Island (FL): StatPearls Publishing; August 22, 2022.
70. Garg A, Gazzard G. Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. *Eye (Lond).* 2020;34(1):60-71. doi:10.1038/s41433-019-0633-6

71. Ansari, E., Chappiti, S., Pavicic-Astalos, J. *et al.* Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes. *BMC Ophthalmol* **22**, 152 (2022). <https://doi.org/10.1186/s12886-022-02361-7>
72. Negri L, Ferreras A, Iester M. Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. *J Ophthalmol.* 2019;2019:4146124. Published 2019 May 2. doi:10.1155/2019/4146124
73. Tripathy K, Geetha R. Latanoprost. [Updated 2023 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK540978/>
74. Baba M , Idriss A, YahyaT, Batty A, Cheikh S. Primary Open Angle Glaucoma: Epidemiological, Clinical and Therapeutic Aspects of 63 Cases at National Hospital Center in Mauritania. *Open Journal of Ophthalmology.* 2020; 10: 229-240. doi: 10.4236/ojoph.2020.103025
75. Sahin AK, Kapti HB, Uzun A. Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma. *Int J Ophthalmol.* 2022;15(3):483-488. Published 2022 Mar 18. doi:10.18240/ijo.2022.03.17,
76. Gandolfi S, Marchini G, Caporossi A, Scuderi G, Tomasso L, Brunoro A. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. *Nutrients.* 2020;12(3):793. Published 2020 Mar 18. doi:10.3390/nu12030793
77. Yu ZK, Chen YN, Aihara M, Mao W, Uchida S, Araie M. Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells. *Mol Vis.* 2007;13:833-839. Published 2007 Jun 11
78. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. *J Ocul Pharmacol Ther.* 2015;31(2):63-77.



79. Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. *Experimental Eye Research*. 2011; 93( 3): 265-270.
80. Chițu I, Voinea LM, Istrate S, Vrapciu A, Ciulovică RC, Tudosescu R. The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial. *Rom J Ophthalmol*. 2019;63(3):222-230.
81. Sayuti K, Harmen, Hondrizal. Pengaruh Lamanya Pemberian Citicoline dalam Memperbaiki Retinal Nerve Fiber Layer (Rnfl) dan Lapang Pandangan pada Primary Open Angle Glaucoma (Poag). *JKA*. 2014; 3(1): 63-67
82. Faiq MA, Wollstein G, Schuman JS, Chan KC. Cholinergic nervous system and glaucoma: From basic science to clinical applications. *Prog Retin Eye Res*. 2019; 72:
83. Oddone F, Rossetti L, Parravano M, et al. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. *Pharmaceuticals (Basel)*. 2021;14(3):281. Published 2021 Mar 20.
84. Rossetti L, Iester M, Tranchina L, et al. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. *J Glaucoma*. 2020;29(7):513-520.
85. García-López C, García-López V, Matamoros JA, et al. The Role of Citicoline and Coenzyme Q10 in Retinal Pathology. *Int J Mol Sci*. 2023;24(6):5072.
86. Wang ,Bin Wei,Xing ya ,et al. Thickness of individual layer at the macula and associated factors.*BMC Ophthalmology*.2020;20(49)
87. Al-Hawasi Abbas,Lagali Neil. Retinal Ganglion cell layer thickness and volume measured by OCT change with age,sex, and axial length in a healthy population.2022;22(278)
88. Tatham J Andrew, Weinreb Robert ,et al. The relationship Between Cup to Disc Ratio and Estimated Number of Retinal Ganglion Cells.2013;54:3205-3214.

89. Ming K, Tsung ,et al. The Role of Retinal Ganglion Cell Structure and Function in Glaucoma. Departement of Ophthalmology Tri-Service General Hospital. National Defense Medical Center.Taiwan.2023
90. Katsura M, Yamaghisi R, et al. Mechanisms of Neuroprotection by Latanaprost for Retinal Ganglion Cell under Hypoxia.Investigative Ophthlamology and Visual Science.Vol.54(412).2013

